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Abstract
In the recent years the nanobiotechnology field and the Journal of Nanobiotechnology readership
have witnessed an increase in interest towards the nanoparticles and their biological effects and
applications. These include bottom-up and molecular self-assembly, biological effects of naked
nanoparticles and nano-safety, drug encapsulation and nanotherapeutics, and novel nanoparticles
for use in microscopy, imaging and diagnostics. This review highlights recent Journal of
Nanobiotechnology publications in some of these areas http://www.jnanobiotechnology.com.
Bottom-up nanobiotechnology and biology-
inspired nanoparticles
Some of the most promising applications of biologically
inspired nanoparticles have so far been in nanobiotech-
nology and in tissue- and cell-specific drug delivery in par-
ticular. Unlike liposomes, dendrimers, metal and
semiconductor nanoparticles, the nanoparticles made of
biopolymers, such as bacterial spores, viruses and alike
are naturally uniform in size and offer precise control for
the surface-displayed targeting groups and their compo-
nents. Furthermore, such biological nanoparticles may be
produced recombinantly relatively easy and at low cost,
and their assembly may be easily followed using a pleth-
ora of molecular and cellular approaches and instrumen-
tal techniques. The stability of nanoparticles made of
biopolymers is one of the limiting factors which will
determine the range of their applications. In their most
recent paper Caldeira and Peabody [1] investigated in vitro
assembly and stability of virus-like icosahedral capsid of
the RNA bacteriophage PP7 particles. Contrary to expecta-
tions, recombinant fusion of the subunits have not stabi-
lized PP7 virus-like particles against thermal
denaturation, whilst disulphide bonds between coat pro-
tein dimers greatly increased the viral particles' stability.
A loading capacity of nanoparticles made of biopolymers
is another important criterion in the use of such nanopar-
ticles as nano-containers for specific targeting applica-
tions. A comprehensive study of the assembly and
stability of canine parvovirus-like particles (CPV) was
conducted by Gilbert et al [2] who employed a novel strat-
egy, based on Fluorescence Correlation Spectroscopy
analysis, to monitor the assembly of a series of truncated
monomeric canine parvovirus VP2 structural proteins and
their GFP fusions. The trancations ranged from 0 (native
protein) to 40 amino acids. Intriguingly, only one trun-
cated variant (-14 amino acids) failed to assemble into a
CPV-like particle, which was confirmed independently
using more traditional confocal and electron microscopy
approaches. The GFP "load" did not prevent nanoparticle
assembly.
The ability to manipulate and direct CPV assembly is of
critical importance in the field of target-specific drug
delivery. Because CPV has naturally high affinity to trans-
ferrin receptors (TfRs), which are often over-expressed on
tumor cells, CPV might be used for specific targeting of
tumour cells directly. Singh et al [3] have utilized this abil-
ity of CPVs and studied targeting of HeLa, HT-29 and
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MDA-MB231 cells and the internalization of native and
modified ("loaded") CPVs. The assembled CPV-like nan-
oparticles were found to withstand conjugation with
chemotherapeutic drugs, remain intact following their
purification and internalise within 2 hours through TfRs
receptors.
Biological effects and therapeutic applications
Traditional strategies towards the tissue-specific drug
delivery utilise cytotoxic drugs attached to targeting moie-
ties (e.g. towards TfRs receptors mediating cell-specific tar-
geting and internalisation). In their recent report
Mondalek et al [4] have shown that nanoparticle internali-
sation can be enhanced by the use of an external magnetic
field and targeted magnetic delivery. To illustrate this, a
model similar to the human round window membrane
has been developed and superparamagnetic iron oxide
(Fe3O4) nanoparticles were magnetically transported
through three co-cultured layers of cells. Such magnetic
gradient-forced transport is minimally invasive, does not
compromise epithelial confluence and has the potential
to enhance the therapeutic benefits of magnetic nanopar-
ticles-based drugs and reduce their toxicity.
Magnetic nanowires are another example of paramagnetic
nanomaterial especially suitable for nanobiotechnology
applications due to their size and anisotropy (unlike tra-
ditional anisotropic magnetic nanoparticles. Prina-Mello
and co-workers have shown that Nickel nanowires, grown
in alumina membranes, can be introduced into adherent
and suspended cells and be used for cell manipulation,
identification and separation [5]. The authors have also
shown that internalised nanowires can be manipulated
(re-oriented) whilst inside the cells without inducing any
anisotropy in the population of adherent cells.
In addition to their ever more increasing use in molecular
separations and targeting, magnetic nanoparticles were
shown to also increase stability, activity and functionality
of enzymes immobilised on the surface of the particles
[6]. Kinetic studies of free and bound Cholesterol oxidase
revealed structural and conformational changes of the
immobilised enzyme which resulted in the reduction of
activation energy upon binding onto iron oxide (Fe3O4)
nanoparticles. The binding to nanoparticles further
improved the storage stability of the enzyme, increased its
tolerance to the variation in reaction pH and its thermal
stability (increased twice at 60°C). The above effects were
observed with particles ranging between 9.7 and 56.4 nm
in size. Protein-nanoparticle interactions and the immo-
bilisation kinetics onto L-aspartic acid-modified iron
oxide (Fe3O4) nanoparticles and 3-mercaptopropionic
acid-modified gold coated Fe3O4/Au nanoparticles has
been reported by Kouassi and Irudayaraj previously [7].
In an independent study, Mukherjee et al reported that the
immobilisation of anti-VEGF antibodies on gold nano-
particles increase the ability of these antibodies to induce
apoptosis in Chronic Lymphocytic Leukemia B cells [8].
The induction of apoptosis with gold-conjugated anti-
VEGF antibodies was significantly higher than the CLL
cells exposed to antibodies alone or to unconjugated gold
nanoparticles. The authors attribute the effect to the
increased concentration of drug and improved intracellu-
lar delivery, although improvements in antibody stability,
conformational changes and the nanoparticles' cytotoxic
effect on the target cells cannot be discounted.
A complex character of the interactions of inorganic nan-
oparticles with viral particles has been investigated by
Elechiguerra et al [9]. The authors unequivocally demon-
strated size- and site-dependent interaction of silver nan-
oparticles with gp120 surface glycoproteins of the HIV-1
virus. The binding and the inhibition of virus binding to
host cells is limited to particles ranging between 1 and 10
nm in size.
In contract to [8,9], Williams et al observed no effect on
cell proliferation or any signs of toxicity when Escherichia
coli were incubated with silica, silica/iron oxide, and gold
nanoparticles [10]. Studying the interaction of inorganic
nanoparticles with biological targets, whether molecules,
viruses, bacteria, cells, tissues or organisms, as well as the
nano-safety aspects and the long-term effects of that inter-
action might present a challenge to the scientific commu-
nity due to the sheer number of materials, nanoparticle
preparation methods and functionalization techniques.
There is no universal "nanoparticle" to fit all the cases,
and the multitude of "grey goo" scenarios, first hinted at
by nanotechnology theorist Dr. K. Eric Drexler in his 1986
book "Engines of Creation", has raised hair on the heads
of many safety officers and researchers active in the field,
including Peter Hoet, Irene Brüske-Hohlfeld and Oleg
Salata who's paper on the health risks associated with the
nanoparticles remains the most cited paper in the Journal
of Nanobiotechnology to date [11].
Concluding remarks
This month the Journal of Nanobiotechnology celebrates
5 years since its creation. On behalf of the Editorial board
I would like to thank all the authors for their precious
work and excellent manuscripts, the reviewers for their
invaluable service to the field and the Editorial Board and
many Editors of other BioMed Central publications for
their continuous support and encouragement. My special
thanks go to the publisher, BioMed Central (London). I
would like to invite the wider scientific community to join
the fast growing readership of this Open Access Journal
and also to consider it for publishing your own work. And
finally, my warmest wishes to everybody for the comingPublish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
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Christmas and the New Year (with apologies to the fol-
lowers of other calendars and religions). This New Year
promises to be the warmest ever but we have yet to see a
manuscript on the use of Nano-bio-technology for solving
this truly Planetary-scale problem of global warming.
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